• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
DAI Huiteng, TIAN Hong, HUANG Jie, CHEN Chao, CAI Di, GAO Xiangdong, YAO Wenbing. Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice[J]. Journal of China Pharmaceutical University, 2017, 48(4): 483-489. DOI: 10.11665/j.issn.1000-5048.20170414
Citation: DAI Huiteng, TIAN Hong, HUANG Jie, CHEN Chao, CAI Di, GAO Xiangdong, YAO Wenbing. Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice[J]. Journal of China Pharmaceutical University, 2017, 48(4): 483-489. DOI: 10.11665/j.issn.1000-5048.20170414
shu

Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice

More Information
    Graphical Abstract
    • Abstract
  • In order to verify whether p-nitrophenylalanine-containing BAFF vaccine can be used as a candidate molecule for the treatment of autoimmune diseases with BAFF over-expression, a soluble mutant of B cell activating factor belonging to the TNF Family(smBAFF)and its pNO2Phe mutant(pNO2Phe65smBAFF), which site specific incorporated pNO2Phe at position 65 of smBAFF, were expressed and purified. In order to evaluate the feasibility of using pNO2Phe65smBAFF to treat BAFF-over-expressed autoimmune diseases, we investigate its Lymphocyte-stimulating capacity, immunogenicity and inhibitory effect of serum on biological activity of natural BAFF. The pharmacological activity of pNO2Phe65smBAFF was evaluated using a cGVHD(graft-versus-host disease)induced SLE mouse model. Results indicated that pNO2Phe65smBAFF, could bind to mouse lymphocytes but could not promote the proliferation of mouse lymphocytes. Moreover, the incorporation of pNO2Phe significantly increased the immunogenicity and induced cross-antibody, which can inhibit the biological activity of natural BAFF. In cGVHD induced SLE mouse model, pNO2Phe65smBAFF can significantly reduce the symptoms of the disease and play a therapeutic role. Therefore, pNO2Phe65smBAFF can be used as a candidate molecule for the treatment of autoimmune diseases with BAFF over-expression.
    • FullText(HTML)
    • References (21)
  • [1]
    Mackay F,Schneider P.Cracking the BAFF code[J].Nat Rev Immunol,2009,9(7):491-502.
    [2]
    Pieper K,Grimbacher B,Eibel H.B-cell biology and development[J].J Allergy Clin Immunol,2013,131(4):959-971.
    [3]
    Campi I,Tosi D,Rossi S,et al.B Cell activating factor(BAFF)and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases[J].Thyroid,2015,25(9):1043-1049.
    [4]
    Wei F,Chang Y,Wei W.The role of BAFF in the progression of rheumatoid arthritis[J].Cytokine,2015,76(2):537-544.
    [5]
    Boneparth A, Woods M, Huang W, et al. The effect of BAFF inhibition on autoreactive B cell selection in murine SLE[J].Mol Med,2016,22:173-182.
    [6]
    Mackay F,Woodcock SA,Lawton P,et al.Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations[J].J Exp Med,1999,190(11):1697-1710.
    [7]
    Stohl W.Inhibition of B cell activating factor(BAFF)in the management of systemic lupus erythematosus(SLE)[J].Exp Rev Clin Immunol,2017,13(6):623-633.
    [8]
    Zouali M,Uy EA.Belimumab therapy in systemic lupus erythematosus[J].Biol Drugs,2013,27(3):225-235.
    [9]
    Scheinberg MA,Hislop CM,Martin RS.Blisibimod for treatment of systemic lupus erythematosus:with trials you become wiser[J].Exp Opin Biol Ther,2016,16(5):723-733.
    [10]
    Richez C,Truchetet M-E,Schaeverbeke T,et al.Atacicept as an investigated therapy for rheumatoid arthritis[J].Exp Opin Investig Drugs,2014,23(9):1285-1294.
    [11]
    Deng DN,Tian H,Yao WB.Advances in therapeutic B-cell vaccines against chronic diseases[J].J China Pharm Univ(中国药科大学学报),2013,44(5):470-475.
    [12]
    Zhao Z,Sun HQ,Wei SS,et al.Multiple B-cell epitope vaccine induces a Staphylococcus enterotoxin B-specific IgG1 protective response against MRSA infection[J].Sci Rep,2015,5:12371.
    [13]
    Kobiyama K,Aoshi T,Narita H,et al.Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist[J].Proc Natl Acad Sci U S A,2014,111(8):3086-3091.
    [14]
    Bohnen C, Wangorsch A, Schulke S, et al. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice[J].Allergy,2013,68(8):1021-1028.
    [15]
    Martins KA,Steffens JT,van Tongeren SA,et al.Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation[J].PLoS ONE,2014,9(2):e89735.
    [16]
    Xie J,Schultz PG.An expanding genetic code[J].Methods,2005,36(3):227-238.
    [17]
    Grunewald J,Tsao ML,Perera R,et al.Immunochemical termination of self-tolerance[J].Proc Natl Acad Sci U S A,2008,105(32):11276-11280.
    [18]
    Grunewald J,Hunt GS,Dong L,et al.Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids[J].Proc Natl Acad Sci U S A,2009,106(11):4337-4342.
    [19]
    Gauba V, Grunewald J, Gorney V, et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids[J].Proc Natl Acad Sci U S A,2011,108(31):12821-12826.
    [20]
    Kessel C,Nandakumar KS,Peters FB,et al.A single functional group substitution in C5a breaks B cell and T cell tolerance and protects against experimental arthritis[J].Arthritis Rheumatol,2014,66(3):610-621.
    [21]
    Liu Y, Xu L, Opalka N, et al. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands[J].Cell,2002,108(3):383-394.
    • Related Articles

  • Related Articles

    [1]LI Zhiyan, LI Xianghui, AI Shichao, YIN Yi, LIU Song, GUAN Wenxian. Application of nanomedicines targeting non-glucose nutrients in tumor starvation therapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 392-399. DOI: 10.11665/j.issn.1000-5048.20220402
    [2]PAN Xiuhua, WU Zhenghong, QI Xiaole. Research status and application progress of CRISPR/Cas9 delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(1): 10-18. DOI: 10.11665/j.issn.1000-5048.20200102
    [3]JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
    [4]SUN Xiaofeng, LIU Tao, LING Yun, CHEN Zhengwei, PAN Zihao, XU Zite, LUO Ling. Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior[J]. Journal of China Pharmaceutical University, 2019, 50(6): 641-647. DOI: 10.11665/j.issn.1000-5048.20190602
    [5]XU Xiangting, WANG Wei. Advances of functionalized carbon nanotubes in diagnosis and treatment of tumor[J]. Journal of China Pharmaceutical University, 2018, 49(2): 165-172. DOI: 10.11665/j.issn.1000-5048.20180205
    [6]CAI Han, LIU Yanhong, YIN Tingjie, ZHOU Jianping, HUO Meirong. Advances in the targeted therapy of tumor-associated fibroblasts[J]. Journal of China Pharmaceutical University, 2018, 49(1): 20-25. DOI: 10.11665/j.issn.1000-5048.20180103
    [7]ZHANG Ran, TIAN Hong, GAO Xiangdong, YAO Wenbing. Application of next generation genome editing technology in gene therapy and biopharmaceuticals[J]. Journal of China Pharmaceutical University, 2014, 45(4): 504-510. DOI: 10.11665/j.issn.1000-5048.20140421
    [8]JIANG Hulin. Biocompatible polymers for gene delivery in cancer gene therapy[J]. Journal of China Pharmaceutical University, 2013, 44(5): 476-481. DOI: 10.11665/j.issn.1000-5048.20130518
    [9]YAO Jing, FAN Ying, ZHOU Jian-ping, LI Fei-yan. Advances on the study of new cationic polymers as gene vectors[J]. Journal of China Pharmaceutical University, 2011, 42(2): 176-181.
    [10]Pharmacokinetics of Magnetic Nanoparticles as Drug Carrier and Their Applications in Cancer Diagnosis and Therapy[J]. Journal of China Pharmaceutical University, 2003, (3): 85-88.

Catalog

    Get Citation
    PDF
    XML
    Article views (818) PDF downloads (1712) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：290221

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return